Phase 1 trial of temozolomide plus irinotecan plus O6- benzylguanine in adults with recurrent malignant glioma

Cancer

Volumn 115, Issue 13, 2009, Pages 2964-2970

  Quinn, Jennifer A ^a   Jiang, Sara Xiaoyin ^a   Reardon, David A ^a   Desjardins, Annick ^a   Vredenburgh, James J ^a   Gururangan, Sridharan ^a   Sampson, John H ^a   McLendon, Roger E ^a   Herndon II, James E ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Irinotecan; Malignant glioma; O6 benzylguanine; Recurrent; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; IRINOTECAN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BRAIN HEMORRHAGE; BRAIN HERNIA; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GLIOMA; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; GUANINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 67649618875     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24336     Document Type: Article

References (25)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17: 2762-2771. (Pubitemid 29415233)
3. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593. (Pubitemid 30636298)
4. Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004;6:21-27. (Pubitemid 38139635)
5. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 2003;97(9 suppl): 2381-2386. (Pubitemid 36444049)
6. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516-1525. (Pubitemid 29220860)
7. Raymond E, Fabbro M, Boige V, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol. 2003;14:603-614. (Pubitemid 41295091)
8. Turner CD, Gururangan S, Eastwood J, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol. 2002;4:102-108. (Pubitemid 34285064)
9. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993;85:271-291. (Pubitemid 23068801)
10. Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9:2940-2949. (Pubitemid 37006309)
11. Prados MD, Yung WK, Jaeckle KA, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004;6:44-54. (Pubitemid 38139639)
12. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35-61. (Pubitemid 27273454)
13. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65:287-291.
14. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res. 2000;6:4110-4118. (Pubitemid 30807107)
15. Patel VJ, Elion GB, Houghton PJ, et al. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res. 2000;6:4154-4157. (Pubitemid 30807113)
16. 6-methylguanine. Cancer Res. 2001;61:53-58. (Pubitemid 32095699)
17. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857. (Pubitemid 29001538)
18. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
19. 6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J Pharmacol Exp Ther. 2006;316:946-954. (Pubitemid 43131025)
20. Okamoto R, Takano H, Okamura T, et al. O-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res. 2002;93:93-102. (Pubitemid 34144717)
21. 6-Methylguanine-DNA methlytransferase is a critical determinant of cytotoxicity for DNA topoisomerase I inhibitors. Presented at Proceeding of the American Association of Cancer Research, San Francisco, CA, April 1-5, 2000.
22. 6-benzylguaninemediated enhancement of chemotherapy. Mol Cancer Ther. 2002;1:943-948.
23. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178-7187. (Pubitemid 46260305)
24. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG.Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
25. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578. (Pubitemid 29368260)